Exagen INC Form 4 insider transactions

Director Tina Susan Nova acquired 13,500 stock options in Exagen Inc. on June 10, 2024, at an exercise price of $1.99.

Exagen Inc.'s President and CEO, John Aballi, recently purchased 40,401 shares of the company's common stock at a price of $1.92 per share.

Kamal Adawi, CFO of Exagen Inc., sold shares of common stock on March 4, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Exagen Inc.'s CEO, John Aballi, acquired 9,804 shares of common stock through the Employee Stock Purchase Plan at a price of $1.91 per share on February 29, 2024, increasing his direct holdings to 600,788 shares.